Johnson & Johnson (JNJ)
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
EDAP TMS S.A. (EDAP)
EDAP Reports Third Quarter 2025 Financial Results
Neurogene Inc. (NGNE)
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Viking Therapeutics Inc. (VKTX)
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
uniQure NV (QURE)
uniQure to Announce Third Quarter 2025 Financial Results
NeoGenomics Inc (NEO)
NeoGenomics to Participate in Upcoming Investor Conferences
REGENXBIO Inc (RGNX)
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
Lantheus Holdings Inc. (LNTH)
Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
Invivyd Inc (IVVD)
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
American Shared Hospital Srvcs (AMS)
American Shared Hospital Services Announces Third Quarter Financial Results Conference Call